Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mela Sciences' MelaFind goes to panel

This article was originally published in The Gray Sheet

Executive Summary

FDA's General and Plastic Surgery Devices advisory panel will meet Nov. 18 to discuss a pre-market approval application for Mela Sciences' non-invasive computer vision system to aid in the detection of melanoma. The computer-controlled multi-spectral dermoscope uses light to image skin through a thin layer of liquid, making lesions under the skin surface visible to the eye; a digital camera inside the probe captures images and differentiates lesions for melanoma risk using pattern recognition software. The panel review was postponed from Aug. 26 to allow FDA more time to arrange the meeting (1"The Gray Sheet" July 26, 2010)

You may also be interested in...

FDA Panel Narrowly Endorses Mela Sciences’ Melanoma Detection System

An FDA advisory panel Nov. 18 narrowly endorsed Mela Sciences’ MelaFind melanoma detection system, voting 8-7, with one abstention, that the benefits outweigh any risks.

Spectral Molecular Imaging Readies IDE For Melanoma Detection Trial

Spectral Molecular Imaging will submit an investigational device exemption application to FDA within three months for its SkinSpect system to aid early melanoma detection.

Regulatory News In Brief

Mela Sciences panel delay: FDA has postponed advisory committee review of Mela Sciences' MelaFind, a non-invasive computer vision system to aid in the detection of melanoma, from Aug. 26 to sometime in November. FDA told the firm it needs more time to arrange the meeting, the firm said July 21 (1"The Gray Sheet" June 28, 2010)

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts